Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2026)
Legend Biotech's (LEGN) quarterly Income from Continuing Operations came in at 55000000.0 in Q1 2026, up 45.54% YoY from 37789115.65 in Q1 2025, and down 179.19% on a QoQ basis from 19700000.0 in Q4 2025.
Powered by 
Analysis
Legend Biotech (LEGN) Income from Continuing Operations (2019 - 2026) Analysis & Trends
Legend Biotech (LEGN) has 8 years of Income from Continuing Operations data on file, last reported at 55000000.0 in Q1 2026.
- Quarterly Income from Continuing Operations rose 45.54% year-over-year to 55000000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 237373000.0 (down 8.81% YoY) and the FY2025 annual result came in at 282600000.0, down 59.63% from the prior year.
- Income from Continuing Operations fell to 55000000.0 in Q1 2026, from 19700000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 17034000.0 in Q4 2024 to a low of 198548000.0 in Q2 2023.
- A 5-year average of 87052000.0 and a median of 85624000.0 in 2022 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations tumbled 32288.91% — and 2024, when it surged 111.74%.
- Tracing LEGN's Income from Continuing Operations over 5 years: stood at 135848000.0 in 2022, then decreased by 6.77% to 145042000.0 in 2023, then soared by 111.74% to 17034000.0 in 2024, then sank by 215.65% to 19700000.0 in 2025, then tumbled by 179.19% to 55000000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 55000000.0 (Q1 2026), 19700000.0 (Q4 2025), and 38457000.0 (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | 601.00 Mn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -13.27 Mn |
| 10 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 77.80 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 77.80 Mn |
| Mar 31, 2026 | -51.90 Mn |
| Dec 31, 2025 | -8.50 Mn |
| Sep 30, 2025 | -38.46 Mn |
| Jun 30, 2025 | -124.20 Mn |
| Mar 31, 2025 | -97.40 Mn |
| Dec 31, 2024 | 54.80 Mn |
| Sep 30, 2024 | -116.45 Mn |
| Jun 30, 2024 | -17.74 Mn |
| Mar 31, 2024 | -59.78 Mn |
| Dec 31, 2023 | -148.81 Mn |
| Sep 30, 2023 | -62.78 Mn |
| Jun 30, 2023 | -198.55 Mn |
| Mar 31, 2023 | -111.85 Mn |
| Dec 31, 2022 | -135.57 Mn |
| Sep 30, 2022 | -84.65 Mn |
| Jun 30, 2022 | -192.91 Mn |
| Mar 31, 2022 | -31.96 Mn |
| Dec 31, 2021 | -410.81 Mn |
| Sep 30, 2021 | -124.75 Mn |